Inhibitors of the sodium-glucose cotransporter type 2 in the diabetes melltius treatment

Abstract

Sodium-glucose co-transporter inhibitors´ drugs (SGLT) work by selectively and reversibility inhibiting at the renal level. Through this mechanism, they reduce glucose reabsorption, which is excreted through urine and thus contribute to normalizing blood glucose. Administration of sodium-glucose co-transporter inhibitors induces favorable changes in glycosylated hemoglobin, body weight and blood pressure, as well as a low risk of hypoglycaemia. Although they are a pharmacological group that can be used as monotherapy, they are mostly used as adjuvants in the treatment of patients with diabetes mellitus who receive drug treatment with other normo or hypoglycemic medications and who have not met control goals. It is important to be alert to possible side effects or adverse reactions to discontinue treatment and take appropriate action. Given this problem, a detailed analysis will be highlighted.